Key Takeaways
- • Cardinal Health (CAH) upgraded its Relative Strength (RS) Rating to the 80-plus percentile on April 23, 2026, crossing a key technical benchmark that institutional investors monitor for stock quality screening.
- • The RS Rating improved from the mid-to-upper 70s range (reported variously as 77–79 in prior readings) to 81–82, indicating the stock is outperforming the majority of equities in price performance over the past 52 weeks.
- • Cardinal Health's 52-week range stands at $129.52 (low) to $233.60 (high), with the all-time closing high of $229.32 set on March 2, 2026; current price near $211 positions the stock 8.4% below its 52-week high.
- • Analyst consensus maintains a 12-month average price target of $244.33, implying 15.61% upside from current levels, with targets ranging from $170 to $275 across 17 analysts tracking the stock.
- • Cardinal Health maintains investment-grade BBB rating from Fitch, supported by strong cash flow generation and recent strategic initiatives including the Solaris Health acquisition and advances in nuclear medicine products.
Summary
Cardinal Health achieved a notable technical milestone on April 23, 2026, when its Relative Strength (RS) Rating—a proprietary Investor's Business Daily metric tracking 52-week price performance relative to all equities—upgraded into the 80-plus percentile. The stock's RS Rating advanced from the 77–79 range to 81–82 levels, signaling improved momentum and relative outperformance in the market.
An RS Rating of 80 or higher is considered a key screening benchmark for institutional investors and quantitative stock-selection models. The metric measures how a stock's price action compares to the broader universe of equities, with a score of 95 indicating outperformance of 95% of all stocks. The upgrade positions Cardinal Health among the upper tier of performers by this technical measure, potentially attracting systematic and momentum-based institutional capital.
Cardinal Health's recent price action reflects a recovery trajectory within a defined range. The stock's 52-week high of $233.60 and all-time closing high of $229.32 (achieved March 2, 2026) bracket the current price level near $211, placing the equity 8.4% below its 52-week high but 39.9% above its 52-week low of $129.52. This positioning suggests the stock has recovered meaningfully from its near-term lows while maintaining room to test prior resistance levels.
Analyst sentiment remains constructive, with 17 covering analysts establishing a consensus 12-month price target of $244.33, implying 15.61% upside from current levels. Target ranges span from $170 to $275, reflecting divergent views on the healthcare services distributor's near-term trajectory. The company maintains investment-grade credit quality, with Fitch affirming its BBB rating in the prior year based on robust cash flow generation. Recent growth catalysts include positive fiscal 2026 guidance, the Solaris Health acquisition, and innovation in nuclear medicine product offerings, which collectively support the improved technical positioning reflected in the RS Rating upgrade.
An RS Rating of 80 or higher is considered a key screening benchmark for institutional investors and quantitative stock-selection models. The metric measures how a stock's price action compares to the broader universe of equities, with a score of 95 indicating outperformance of 95% of all stocks. The upgrade positions Cardinal Health among the upper tier of performers by this technical measure, potentially attracting systematic and momentum-based institutional capital.
Cardinal Health's recent price action reflects a recovery trajectory within a defined range. The stock's 52-week high of $233.60 and all-time closing high of $229.32 (achieved March 2, 2026) bracket the current price level near $211, placing the equity 8.4% below its 52-week high but 39.9% above its 52-week low of $129.52. This positioning suggests the stock has recovered meaningfully from its near-term lows while maintaining room to test prior resistance levels.
Analyst sentiment remains constructive, with 17 covering analysts establishing a consensus 12-month price target of $244.33, implying 15.61% upside from current levels. Target ranges span from $170 to $275, reflecting divergent views on the healthcare services distributor's near-term trajectory. The company maintains investment-grade credit quality, with Fitch affirming its BBB rating in the prior year based on robust cash flow generation. Recent growth catalysts include positive fiscal 2026 guidance, the Solaris Health acquisition, and innovation in nuclear medicine product offerings, which collectively support the improved technical positioning reflected in the RS Rating upgrade.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.